Surgery Partners (NASDAQ:SGRY) Given Overweight Rating at Cantor Fitzgerald

Surgery Partners (NASDAQ:SGRY)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research report issued on Tuesday,Benzinga reports. They currently have a $18.00 price objective on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 12.85% from the stock’s current price.

Several other equities research analysts also recently issued reports on SGRY. Jefferies Financial Group restated a “buy” rating and issued a $17.00 price objective on shares of Surgery Partners in a research note on Wednesday, May 6th. Zacks Research upgraded shares of Surgery Partners from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Surgery Partners in a report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Surgery Partners presently has an average rating of “Moderate Buy” and a consensus target price of $19.80.

Surgery Partners Price Performance

NASDAQ SGRY opened at $15.95 on Tuesday. The stock has a 50-day simple moving average of $15.49 and a 200 day simple moving average of $14.43. Surgery Partners has a twelve month low of $11.41 and a twelve month high of $24.10. The stock has a market capitalization of $2.09 billion, a PE ratio of -26.58, a P/E/G ratio of 4.64 and a beta of 1.92. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.69 and a current ratio of 1.86.

Surgery Partners (NASDAQ:SGRY) last released its earnings results on Monday, August 10th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.04. The firm had revenue of $848.90 million for the quarter, compared to analyst estimates of $830.03 million. Surgery Partners had a positive return on equity of 1.04% and a negative net margin of 2.28%.The company’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.17 EPS. Research analysts anticipate that Surgery Partners will post 0.25 EPS for the current year.

Hedge Funds Weigh In On Surgery Partners

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its holdings in shares of Surgery Partners by 239.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,907 shares of the company’s stock worth $35,000 after buying an additional 2,051 shares in the last quarter. Fifth Third Bancorp grew its position in Surgery Partners by 5,324.0% during the 1st quarter. Fifth Third Bancorp now owns 4,068 shares of the company’s stock worth $48,000 after acquiring an additional 3,993 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in Surgery Partners by 45,640.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company’s stock worth $49,000 after acquiring an additional 2,282 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in Surgery Partners during the 3rd quarter valued at $121,000. Finally, Alpine Global Management LLC bought a new position in Surgery Partners in the 4th quarter valued at $175,000.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Second-quarter revenue rose 2.7% year over year to $848.9 million, exceeding the $830.0 million consensus estimate. Adjusted earnings were $0.10 per share, ahead of the $0.06 analyst estimate and the primary reason for the favorable market reaction. Surgery Partners Beats Q2 Sales Expectations
• Positive Sentiment: Same-facility revenue increased 5.0%, driven mainly by a 4.8% increase in revenue per case, while same-facility cases rose 0.3%. Year-to-date revenue was up 3.6% to $1.66 billion. Surgery Partners Reports Q2 Results
• Positive Sentiment: Management reaffirmed full-year 2026 revenue guidance of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, excluding the pending Idaho Falls divestiture. The transaction is expected to improve cash conversion and reduce leverage if completed. Surgery Partners Announces Q2 Results and Reaffirms Guidance
• Positive Sentiment: Brokerages’ consensus price target is $21.60, above the stock’s recent trading level, suggesting analysts see meaningful potential upside. Surgery Partners Receives Consensus Target Price
• Neutral Sentiment: The company ended the quarter with $216.7 million in cash, $617.8 million of revolver capacity and approximately 4.4x net debt to EBITDA, leaving balance-sheet management important for investors.
• Negative Sentiment: GAAP net loss attributable to Surgery Partners widened to $15.0 million from $2.5 million a year earlier. Adjusted EBITDA declined to $125.2 million from $129.0 million, reducing the margin to 14.7% from 15.6%. Operating cash flow also fell to $59.3 million from $81.3 million. Surgery Partners Q2 Earnings Snapshot
• Negative Sentiment: Reported insider activity shows executives made no open-market purchases and completed multiple sales during the past six months, a potentially cautious signal.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.